KURA
Price
$11.04
Change
-$0.69 (-5.88%)
Updated
Sep 23 closing price
Capitalization
1.04B
35 days until earnings call
Intraday BUY SELL Signals
RLAY
Price
$18.03
Change
-$1.32 (-6.82%)
Updated
Sep 23 closing price
Capitalization
4.24B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs RLAY

KURA vs RLAY Comparison Chart in %
View a ticker or compare two or three
VS
KURA vs. RLAY commentary
Sep 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and RLAY is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
KURA vs RLAY: Fundamental Ratings
KURA
RLAY
OUTLOOK RATING
1..100
8669
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
4135
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (64) in the Biotechnology industry is in the same range as RLAY (77) in the null industry. This means that KURA’s stock grew similarly to RLAY’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RLAY (100) in the null industry. This means that KURA’s stock grew similarly to RLAY’s over the last 12 months.

RLAY's SMR Rating (97) in the null industry is in the same range as KURA (99) in the Biotechnology industry. This means that RLAY’s stock grew similarly to KURA’s over the last 12 months.

RLAY's Price Growth Rating (35) in the null industry is in the same range as KURA (41) in the Biotechnology industry. This means that RLAY’s stock grew similarly to KURA’s over the last 12 months.

RLAY's P/E Growth Rating (8) in the null industry is significantly better than the same rating for KURA (100) in the Biotechnology industry. This means that RLAY’s stock grew significantly faster than KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURARLAY
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 17 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
88%
COMPARISON
Comparison
Sep 24, 2026
Stock price -- (KURA: $11.04 vs. RLAY: $18.03)
Brand notoriety: KURA and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 166% vs. RLAY: 171%
Market capitalization -- KURA: $1.04B vs. RLAY: $4.24B
KURA [@Biotechnology] is valued at $1.04B. RLAY’s [@Biotechnology] market capitalization is $4.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.53B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 0 FA rating(s) are green while RLAY’s FA Score has 1 green FA rating(s).

  • KURA’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 5 TA indicator(s) are bullish while RLAY’s TA Score has 4 bullish TA indicator(s).

  • KURA’s TA Score: 5 bullish, 5 bearish.
  • RLAY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KURA is a better buy in the short-term than RLAY.

Price Growth

KURA (@Biotechnology) experienced а -1.43% price change this week, while RLAY (@Biotechnology) price change was -4.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.56%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was +7.23%.

Reported Earning Dates

KURA is expected to report earnings on Oct 29, 2026.

RLAY is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-0.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KURA
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPWCX9.870.04
+0.41%
American Beacon Stephens Sm Cp Gr C
TGVLX61.880.15
+0.24%
Touchstone Dynamic Large Cap Growth R6
JEPAX14.060.02
+0.14%
JPMorgan Equity Premium Income A
CWICX82.400.08
+0.10%
American Funds Cptl Wld Gr&Inc 529-C
FMUCX16.65-0.01
-0.06%
Federated Hermes Muni and Stock Adv C

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with XNCR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
+1.12%
XNCR - KURA
53%
Loosely correlated
+0.52%
IMVT - KURA
52%
Loosely correlated
+0.30%
VIR - KURA
49%
Loosely correlated
+5.70%
RLAY - KURA
48%
Loosely correlated
+6.38%
DYN - KURA
47%
Loosely correlated
+0.12%
More